Division of Agilent Technologies Inc.
Latest From Varian Inc.
The ever-growing importance of the Chinese market and the increasing presence of Chinese players in the global medtech arena has not gone amiss in 2017, and the new year began with a flurry of announcements of further East-West partnerships being forged, including one by next-gen sequencing leader Illumina and by cancer therapy specialist Varian Medical Systems. Additionally, global investment firm Ally Bridge sealed a deal with LifeTech to co-invest in medtech companies looking to tackle China.
The third of three Winners and Losers features covering the companies that announced sales and earnings results in late July and early August looks at major companies that only market medical devices aside from the orthopedics device makers that were covered in an earlier Winners and Losers feature.
FDA approved Cochlear Ltd.’s Nucleus Hybrid L24 cochlear implant system, the first implantable device for adults with severe or profound sensorineural hearing loss. Volcano’s instant wave-Free Ratio (iFR) intravascular imaging modality is cleared based on ADVISE II results. More product news.
Genetic testing firm 23andMe has stopped providing its genetic tests to consumers, following a warning letter from FDA. The agency has reached a $1.25 million settlement with Johnson & Johnson’s Advanced Sterilization Products group. HHS agencies announced delay in health IT meaningful use implementation. More news.
- Medical Devices
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Agilent Technologies Inc.
- Senior Management
Gary W Rogerson, PhD, Chmn. & CEO
G. Edward McClammy, SVP, CFO
- Contact Info
Phone: (650) 213-8000
3120 Hansen Way
Palo Alto, CA 94304-1030
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.